Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-07-29 | 2025-07-29 |
| Drug Identification Number | 02401614 | 02401614 |
| Brand name | MED-RIVASTIGMINE | MED-RIVASTIGMINE |
| Common or Proper name | Rivastigmine | Rivastigmine |
| Company Name | GENERIC MEDICAL PARTNERS INC | GENERIC MEDICAL PARTNERS INC |
| Ingredients | RIVASTIGMINE | RIVASTIGMINE |
| Strength(s) | 1.5MG | 1.5MG |
| Dosage form(s) | CAPSULE | CAPSULE |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | Bottle of 100 Capsules | Bottle of 100 Capsules |
| ATC code | N06DA | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
| Anticipated start date | 2025-07-29 | 2025-07-29 |
| Actual start date | 2025-07-29 | 2025-07-29 |
| Estimated end date | 2025-09-15 | 2025-09-15 |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | Shortages of Rivastigmine capsules, 1.5mg, 3.0mg, 4.5mg and 6.0 mg, bottles of 100 capsules have caused a stock reduction of Med-Rivastigmine, bottles of 100. Med-Rivastigmine 1.5 mg Blister of 56 Capsules continues to be available. | Shortages of Rivastigmine capsules, 1.5mg, 3.0mg, 4.5mg and 6.0 mg, bottles of 100 capsules have caused a stock reduction of Med-Rivastigmine, bottles of 100. Med-Rivastigmine 1.5 mg Blister of 56 Capsules continues to be available. |
| Health Canada comments |